Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Galapagos aquires Sareum's drug discovery assets

This article was originally published in Scrip

Executive Summary

Galapagos, the Belgian drug discovery company, is to acquire the structure-based drug discovery assets of UK-based Sareum for €695,000. Galapagos will acquire all of Sareum's ongoing structure-based drug discovery services contracts, a set of protein target structures called the Crystal Bank, a fragment screening library and equipment needed to perform structure-based drug discovery. Sareum's structure-based platform uses X-ray crystallography to discover chemical fragments for recombination, which the company says has accelerated drug discovery in many of its programmes. Galapagos said the assets would strengthen the position of its service division BioFocus DPI and that the acquisition would contribute slightly to the subsidiary's revenue target for this year. The Belgian company has reiterated its full year revenue guidance of €75-80 million. BioFocus DPI will also acquire five of Sareum's employees to operate the platform. Sareum began considering the sale of all or part of its business in May after it began a review of its operations amid difficult trading (ScripOnline, May 7th, 2008).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts